Abstract
Fatigue is probably the most common symptom from both acute and chronic illnesses. It can be defined as a pervasive sense of tiredness or lack of energy that may not be related to exertion. Fatigue is transitory in most cases, however, if it is prolonged or disabling, a significant problem such as chronic fatigue syndrome (CFS) may be warranted. CFS is a complex, debilitating disorder characterized by severe persistent or relapsing fatigue for at least 6 months and a group of characteristic but nonspecific symptoms. Many researchers have proposed that CFS has a specific underlying cause. Currently, however, there is no evidence that supports this view. In addition, since there is no specific physical findings or definitive laboratory tests for consistent biological markers, the diagnosis of CFS depends on operational criteria that do not afford validity and is primarily a diagnosis by exclusion. The prognosis is poor and often the disability and impairment of daily function and performance may be prolonged. The limited understanding of CFS has complicated the management of this disorder. Therefore, the treatment of CFS may be variable and should be tailored to each patient-it should include exercise, diet, good sleep hygiene, antidepressants, and other medications, depending on the patient's clinical presentation.
References
1. Matthews DA, Manus P, Lane TJ. Evaluation and management of patients with chronic fatigue. Am J Med Sci. 1991. 302:269–277.
2. Epstein KR. The chronically fatigued patient. Medical Clinics of North America. 1995. 79:315–327.
3. Wessely S, Hotopf M, Sharpe M. Chronic fatigue and its syndrome. 1998. Oxford ; New York: Oxford University Press.
5. Buchwald D, Sullivan JL, Komaroff AL. Frequency of 'chronic active Epstein-Barr virus infection' in a general medical practice. JAMA. 1987. 257:2303–2307.
6. Jones JF, Ray CG, Minnich LL, Hicks MJ, Kibler R, Lucas DO. Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early antigen antibodies. Ann Intern Med. 1985. 102:1–7.
7. Holmes GP, Kaplan JE, Gantz NM, et al. Chronic Fatigue Syndrome: a working case definition. Ann Intern Med. 1988. 108:387–389.
8. Fukuda K, Straus SE, Hickie I, et al. The Chronic Fatigue Syndrome: a comprehensive approach to its definition and study. Ann Intern Med. 1994. 121:953–959.
9. Carruthers BM, Jain AK, Meirleir KL, Peterson DL, Klimas NG, et al. Myalgic encephalomyelitis/Chronic fatigue syndrome: Clinical working case definition, diagnostic and treatment protocols. Journal of Chronic Fatigue Syndrome. 2003. 11:7–115.
10. Lloid AR. Chronic fatigue and chronic fatigue syndrome: Shifting boundaries and attributions. Am J Med. 1998. 105:7S–10S.
11. David A, Pelosi A, McDonald E, et al. Tired, weak, or in need of rest: fatigue among general practice attenders. BMJ. 1990. 301:1199–1202.
13. Jason LA, Richman JA, Rademaker AW, et al. A community-based study of chronic fatigue syndrome. Arch Intern Med. 1999. 159:2129–2137.
14. Wessely S, Chalder T, Hirsch S, Wallace P, Wright D. The prevalence and morbidity of chronic fatigue and chronic fatigue syndrome: a prospective primary care study. Am J Public Health. 1997. 87:1449–1455.
16. Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G. Dimensional assessment of chronic fatigue syndrome. J Psychosom Res. 1994. 38:383–392.
17. Reyes M, Dobbins JG, Nisenbaum R, Subedar NS, Randall B, Reeves WC. Chronic fatigue syndrome progression and self-defined recovery: evidence from the CDC surveillance system. J Chronic Fatigue Syndr. 1999. 5:7–17.
18. Russo J, Katon W, Clark M, Kith P, Sintay M, Buchwald D. Longitudinal changes associated with improvement in chronic fatigue patients. J Psychosom Res. 1998. 45:67–76.
20. CDC. Chronic fatigue syndrome. 1998. Atlanta U.S.: DHHS.
21. Powell R, Dolan R, Wessely S. Attributions of self-esteem in depression and chronic fatigue syndromes. J Psychosom Res. 1990. 34:665–673.
22. Demitrack MA, Dale JK, Straus SE, et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab. 1991. 73:1224–1234.
23. Sharpe M, Clements A, Hawton K, et al. Increased prolactin response to buspirone in chronic fatigue syndrome. J Affect Disord. 1996. 41:71–76.
24. Komaroff AL, Fagioli LR, Doolittle TH, et al. Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. Am J Med. 1996. 101:281–290.
25. Jason LA, Richman JA, Friedberg F, Wagner L. Politics, science, and the emergence of a new disease: The case of chronic fatigue syndrome. Am Psychol. 1997. 52:973–983.
26. Evengard B, Schacterle RS, Komaroff AL. Chronic fatigue syndrome : new insights and old ignorance. J Intern Med. 1999. 246:455–469.
27. Johnson SK, Deluca J, Fiedler N, et al. Cognitive functioning of patients with chronic fatigue syndrome. Clin Infect Dis. 1994. 18:Suppl 1. S84–S85.
28. Freeman R, Komaroff AL. Does the chronic fatigue syndrome involve the autonomic nervous system? Am J Med. 1997. 102:357–362.
29. Landay AL, Jessop C, Lennette ET, et al. Chronic fatigue syndrome : clinical condition associated with immune activation. Lancet. 1991. 338:707–712.
30. Barker E, Fujimura SF, Fadem MB, et al. Immunologic abnormalities associated with chronic fatigue syndrome. Clin Infect Dis. 1994. 18:Suppl 1. S136–S141.
31. Patnaik M, Komaroff AL, Conley E, et al. Prevalence to IgM antibodies to human herpes virus 6 early antigen(p41/38) in patients with chronic fatigue syndrome. J Infect Dis. 1995. 172:1364–1367.
32. Dobbins JG, Lipkin WI, Even C, et al. Borna disease virus in the Atlanta CFS case-control study. J Chron Fatigue Syn. 1996. 2:82–83.
33. Suhadolnik RJ, Reichenbach NL, Hitzges P, et al. Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis. 1994. 18:Suppl 1. S96–S104.
34. Suhadolnik RJ, Peterson DL, O'Brien K, et al. Further evidence for biochemical defects in the 2-5A synthetase/RNase L and PKR pathway in chronic fatigue syndrome. J Chron Fatigue Syn. 1996. 2:123.
35. Suhadolnik RJ, Peterson DL, O'Brien K, et al. Biochemical evidence for a novel molecular weight 2-5A dependent RNase L in chronic fatigue syndrome. J Interferon Cytokine Res. 1997. 17:377–385.
37. Chalder T, Berelowitz G, Pawlikowska T, et al. Development of a fatigue scale. J Psychosom Res. 1993. 17:147–153.
38. NIAID. Chronic fatigue syndrome. Information for physicians. 1996. Atlanta U.S.: DHHS.
39. Fulcher KY, White PD. Randomized controlled trial of graded exercise in patients with the chronic fatigue syndrome. BMJ. 1996. 314:1647–1652.
40. Depart of Health(UK). A report of the CFS/ME working group : Report to the Chief Medical Officer of an independent working group. 2002.
41. AHRQ Publication No. 02-E001. Evidence report/technology assessment No. 42 : Defining and managing chronic fatigue syndrome. 2001.
42. Bagnall AM, Whiting P, Wright K, Sowden AJ. The effectiveness of interventions used in the treatment/management of chronic fatigue syndrome and/or myalgic encephalomyelitis in adults and children. The NHS Centre for Reviews and Dissemination. 2001. New York: University of York.
43. Whiting P, Bagnall AM, Sowden AJ, Cornell JE, Mulrow CD, Ramirez G. Interventions for the treatment and management of chronic fatigue syndrome: A systematic review. JAMA. 2001. 286:1360–1368.
44. Veterans Health Administration, Depart of Defence. VHA/DoD clinical practice guideline for the management of medical unexplained symptoms : chronic pain and fatigue Version 1.0. 2002.